QbD and Simulation-based Design for Enhanced Bioavailability
David Grant Symposium 2014
Colorcon Modified Release Forum 2014
BEND, Ore.--(BUSINESS WIRE)--Agere Pharmaceuticals, Inc., a leading innovator in oral bioavailability solutions, announced today that it will present case studies based on the company's Quadrant 2 solubilization platform at three conferences in May. Quadrant 2 is the first formulation technology to follow quality by design (QbD) guidelines and to combine materials science and molecular modeling to deliver optimized formulations for poorly soluble drugs.
For more information, please contact Agere at email@example.com.
Agere is a leading CDMO focused on improving the oral bioavailability of insoluble active pharmaceutical ingredients (APIs). The company supports clients from screening to identify the optimal solubilization technology, through formulation design and development into cGMP manufacturing for Phase I through Phase IIb clinical trials. All services follow QbD guidelines and are delivered on a fee-for-service basis. Agere's proprietary formulation design platform, Quadrant 2 , enables the company to deliver a customized solution for every compound to serve each individual client's requirements. The company is located in Bend, OR. For information: www.agerepharma.com.
Agere Pharmaceuticals and Quadrant 2 are trademarks owned by Agere Pharmaceuticals, Inc.
For a Complete Version of this BUSINESS WIRE Press Release